Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry

被引：0

作者：

Hernando Cubero, J. ^{[1
]}

Lago, N. Martinez ^{[2
]}

Mitjavila, M. ^{[3
]}

Garcia-Burillo, A. ^{[4
]}

Pubul, V. ^{[5
]}

Bello, P. ^{[6
]}

Cano, J. M. ^{[7
]}

Llana, B. ^{[8
]}

Castellon, M. ^{[9
]}

Rodeno, E. ^{[10
]}

Pineiro, A. ^{[11
]}

Soldevilla, C. ^{[12
]}

Nevares, M. ^{[13
]}

Aller, J. ^{[14
]}

Anido Herranz, U. ^{[15
]}

Carnero Lopez, B. ^{[16
]}

Nogareda, Z. ^{[5
]}

Garcia Alvarez, A. ^{[17
]}

Jimenez Fonseca, P. ^{[18
]}

Capdevila Castillon, J. ^{[19
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Hosp Arquitecto Marcide, CHUF Complejo Hosp Univ Ferrol, Med Oncol, Ferrol, Spain

[3] Hosp Univ Puerta Hierro, Nucl Med, Majadahonda, Spain

[4] Vall dHebron Univ Hosp, Nucl Med, Barcelona, Spain

[5] Complexo Hosp Univ Santiago Compostela, Nucl Med, Santiago De Compostela, Spain

[6] Hosp Univ & Politecn La Fe, Nucl Med, Valencia, Spain

[7] Hosp Gen Ciudad Real, Med Oncol Dept, Ciudad Real, Spain

[8] Hosp Univ Cent Asturias, Nucl Med, Oviedo, Spain

[9] Hosp Clin Univ Virgen de la Arrixaca, Nucl Med, El Palmar, Spain

[10] Hosp Univ Cruces, Nucl Med, Baracaldo, Spain

[11] Hosp Univ Virgen de las Nieves, Nucl Med, Granada, Spain

[12] Hosp Santa Creu & Sant Pau, Nucl Med, Barcelona, Spain

[13] Hosp Univ Burgos, Nucl Med, Burgos, Spain

[14] Hosp Univ Puerta De Hierro, Endocrinol, Majadahonda, Spain

[15] CHUS Complejo Hosp Univ Santiago de Compostela SE, Med Oncol, La Coruna, Spain

[16] Hosp Univ Lucus Augusti, Med Oncol, Lugo, Spain

[17] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[18] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain

[19] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1157P

引用

页码：S756 / S756

页数：1

共 50 条

[21] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors: current state and future perspectives
Baum, Richard P.
Puranik, Ameya D.
Kulkarni, Harshad R.
INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2015, 2 (02) : 151 - 158
[22] A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)
Duan, H.
Ferri, V
Fisher, G.
Shaheen, S.
Davidzon, G.
Moradi, F.
Nguyen, J.
Franc, B.
Iagaru, A.
Mari, Aparici C.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 181 - 181
[23] Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
Duan, Heying
Girod, Bradley
Ninatti, Gaia
Ferri, Valentina
Kunz, Pamela
Fisher, George
Moradi, Farshad
Davidzon, Guido
Franc, Benjamin
Iagaru, Andrei
Aparici, Carina Mari
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[24] Toxicity Update on the First Real World Experience of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET) Since US FDA Approval
Konda, Bhavana
Vogt, Sherry Mori
Rogers, Sherise
Grenade, Cassandra
Verschraegen, Claire
Zhou, Ye
Goyal, Ashima
Natwa, Mona
Wright, Chadwick
Hussein, Akram
Barr, Hallie
Konate, Dramane
Brown, Andrew
Batdorf, Rochelle
Williams, Bonnie
Wei, Lai
Shah, Manisha
PANCREAS, 2020, 49 (03) : 473 - 473
[25] Efficacy of the Chronic Lanreotide Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP/NET) after Peptide Receptor Radionuclide Therapy (PRRT)
Szalus, N.
Kaminski, G.
Podgajny, Z.
Dziuk, E.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 137 - 137
[26] First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.
Konda, Bhavana
Rogers, Sherise C.
Grenade, Cassandra Natalie
Verschraegen, Claire F.
Zhou, Ye
Goyal, Ashima
Natwa, Mona
Wright, Chadwick
Hussein, Akram
Barr, Hallie
Konate, Dramane
Brown, Andrew
Batdorf, Rochelle
Williams, Bonnie
Zhao, Songzhu
Wei, Lai
Shah, Manisha H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Quality of life assessment following peptide receptor radionuclide therapy (PRRT) of pancreatic neuroendocrine tumor (P-NET)
Marinova, Milka
Muecke, Martin
Mahlberg, Lukas
Essler, Markus
Cuhls, Henning
Radbruch, Lukas
Ahmadzadehfar, Hojjat
JOURNAL OF NUCLEAR MEDICINE, 2016, 57
[28] Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Bertani, E.
Chiappa, A.
Fazio, N.
Grana, C.
Bodei, L.
Falconi, M.
Ravizza, D.
Spada, F.
Andreoni, B.
NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 285 - 285
[29] Peptide receptor radionuclide therapy in patients with pulmonary neuroendocrine tumors: our experience.
Minutoli, F.
Cardile, D.
Cucinotta, M.
Quartuccio, N.
Gangemi, V.
Sindoni, A.
Baldari, S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S531 - S531
[30] Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
Camus, Baptiste
Cottereau, Anne-Segolene
Palmieri, Lola-Jade
Dermine, Solene
Tenenbaum, Florence
Brezault, Catherine
Coriat, Romain
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 18

← 1 2 3 4 5 →